132 related articles for article (PubMed ID: 8583478)
1. Controlling blood pressure throughout the day: issues in testing a new anti-hypertensive agent.
Weber MA; Neutel JM; Smith DH
J Hum Hypertens; 1995 Nov; 9 Suppl 5():S29-35. PubMed ID: 8583478
[TBL] [Abstract][Full Text] [Related]
2. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
Mallion JM; Goldberg AI
Blood Press Suppl; 1996; 2():82-6. PubMed ID: 8913546
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure effects of the angiotensin II receptor blocker, losartan.
Weber MA; Byyny RL; Pratt JH; Faison EP; Snavely DB; Goldberg AI; Nelson EB
Arch Intern Med; 1995 Feb; 155(4):405-11. PubMed ID: 7848024
[TBL] [Abstract][Full Text] [Related]
4. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension.
Chan JC; Critchley JA; Lappe JT; Raskin SJ; Snavely D; Goldberg AI; Sweet CS
J Hum Hypertens; 1995 Sep; 9(9):765-71. PubMed ID: 8551492
[TBL] [Abstract][Full Text] [Related]
5. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
[TBL] [Abstract][Full Text] [Related]
6. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive efficacy of the angiotensin II AT1-receptor antagonist losartan: results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring. Ambulatory Blood Pressure Monitoring Study Group.
Byyny RL
Blood Press Suppl; 1996; 2():71-7. PubMed ID: 8913544
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of losartan.
Goldberg A; Sweet C
Can J Cardiol; 1995 Aug; 11 Suppl F():27F-32F. PubMed ID: 7664215
[TBL] [Abstract][Full Text] [Related]
9. The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension.
Ogihara T; Yoshinaga K
Blood Press Suppl; 1996; 2():78-81. PubMed ID: 8913545
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients.
de la Sierra A; Gil-Extremera B; Calvo C; Campo C; García-Puig J; Márquez E; Oliván J; Roca Cusachs A; Sanz de Castro S; Pontes C; Delgadillo J
J Hum Hypertens; 2004 Mar; 18(3):215-22. PubMed ID: 14973517
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy of morning versus evening administration of olmesartan in uncomplicated essential hypertension.
Smolensky MH; Hermida RC; Portaluppi F
Chronobiol Int; 2007; 24(1):171-81. PubMed ID: 17364587
[TBL] [Abstract][Full Text] [Related]
12. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
[TBL] [Abstract][Full Text] [Related]
13. Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients.
Hermida RC; Ayala DE; Chayan L; Mojon A; Fernandez JR
Chronobiol Int; 2009 Jan; 26(1):61-79. PubMed ID: 19142758
[TBL] [Abstract][Full Text] [Related]
14. Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol.
Radauceanu A; Boivin JM; Bernaud C; Fay R; Zannad F;
Fundam Clin Pharmacol; 2004 Aug; 18(4):483-91. PubMed ID: 15312156
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.
Lacourcière Y; Asmar R
Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1181-7. PubMed ID: 10619580
[TBL] [Abstract][Full Text] [Related]
16. [Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK954, in patients with essential hypertension].
Hagino T; Abe K; Tsunoda K; Yoshinaga K
Nihon Jinzo Gakkai Shi; 1992 Feb; 34(2):133-40. PubMed ID: 1588765
[TBL] [Abstract][Full Text] [Related]
17. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease.
Gansevoort RT; de Zeeuw D; Shahinfar S; Redfield A; de Jong PE
J Hypertens Suppl; 1994 Jul; 12(2):S37-42. PubMed ID: 7965264
[TBL] [Abstract][Full Text] [Related]
18. Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies.
Omboni S; Malacco E; Mallion JM; Volpe M; Zanchetti A;
J Hypertens; 2012 Jul; 30(7):1468-77. PubMed ID: 22573127
[TBL] [Abstract][Full Text] [Related]
19. The future role of losartan.
Hansson L
J Hum Hypertens; 1995 Nov; 9 Suppl 5():S55-8. PubMed ID: 8583483
[TBL] [Abstract][Full Text] [Related]
20. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study.
Mallion JM; Chamontin B; Asmar R; De Leeuw PW; O'Brien E; Duprez D; O'Rourke MF; Rahn KH; Romero R; Battegay E; Hitzenberger G; Safar ME;
Am J Hypertens; 2004 Mar; 17(3):245-51. PubMed ID: 15001199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
